TGF-beta activated kinase 1 (TAK1)-binding protein 1 mRNA (TAB1 mRNA) (TAB1 mRNA)

TAB1 mRNA encodes the TGF-beta activated kinase 1 binding protein 1 (TAB1), a critical adapter protein that regulates the TAK1 (MAP3K7) and p38 alpha (MAPK14) signaling pathways [1, 7]. TAB1 is unique in its ability to trigger the autophosphorylation and activation of p38 alpha independently of canonical MKK3/6 kinases, particularly under conditions of environmental stress or ischemia [2, 13, 15]. It also functions within a signalosome complex with TAB2 or TAB3 to facilitate the activation of TAK1, which subsequently stimulates downstream NF-kappaB and JNK pathways to drive inflammatory and immune responses [6, 11, 12]. In disease states, the overexpression of TAB1 mRNA is frequently observed in chronic inflammatory conditions, various forms of fibrosis (including pulmonary, renal, and hepatic), and several malignancies such as non-small cell lung cancer and colorectal cancer [4, 9, 18, 20]. High TAB1 levels have been linked to tumor progression and chemoresistance in ovarian cancer patients [17, 19]. Therapeutic strategies currently under investigation focus on silencing TAB1 mRNA through RNA interference (siRNA) or microRNA-based mimics to downregulate protein expression, thereby dampening pathological signaling cascades and sensitizing tumor cells to conventional therapies [8, 17, 20].

Other names

MAP3K7IP1TAK1-binding protein 13'-Tab1Mitogen-activated protein kinase kinase kinase 7-interacting protein 1TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 mRNA

Targeting of TAB1 mRNA via RNA interference (siRNA/shRNA) or microRNA mimics triggers the degradation of the transcript or suppresses its translation, leading to reduced levels of the TAB1 adapter protein and subsequent inhibition of the TAK1, p38 MAPK, and NF-kappaB signaling pathways.